Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Uterine Cervical Neoplasms 9Squamous Cell Carcinoma of Head and Neck 9Lung Neoplasms 8Carcinoma, Non-Small-Cell Lung 8Oropharyngeal Neoplasms 6Small Cell Lung Carcinoma 4Nasopharyngeal Carcinoma 4Mesothelioma, Malignant 4Urinary Bladder Neoplasms 3Mouth Neoplasms 3Lymphoid Interstitial Pneumonia 3Laryngeal Neoplasms 3Carcinoma 3Adenocarcinoma of Lung 3Vaginal Neoplasms 2Triple Negative Breast Neoplasms 2Tongue Neoplasms 2Stomach Neoplasms 2Ovarian Neoplasms 2Hypopharyngeal Neoplasms 2Ganglioneuroblastoma 2Carcinoma, Transitional Cell 2Brenner Tumor 2Urethral Neoplasms 1Ureteral Neoplasms 1Stage II Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7 1Solitary Fibrous Tumor, Pleural 1Sinonasal Squamous Cell Carcinoma 1Salivary Gland Neoplasms 1Resectable Intrahepatic Cholangiocarcinoma 1

Interventions

atezolizumab 2Specimen Handling 2Magnetic Resonance Spectroscopy 2talazoparib 1olaparib 1cediranib 1Radiotherapy 1Radiation 1Platinum 1Etoposide 1Cisplatin 1Carboplatin 1Biopsy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Extensive Stage Lung Small Cell Carcinoma × Platinum × Clear all
NCT02899728 2023-10-17

Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 2 Terminated
9 enrolled 4 charts

Extensive Stage Lung Small Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡